Department of Orthopaedic Surgery, Mie Postgraduate School of Medicine, Tsu City, Mie Prefecture, Japan.
J Surg Oncol. 2010 Sep 1;102(3):271-5. doi: 10.1002/jso.21602.
We recently developed and established a new surgical therapy combining photodynamic surgery and radiodynamic therapy using acridine orange (AO) therapy after marginal or intralesional tumor resection, providing excellent limb function to sarcoma patients. The present study evaluated local recurrence rate and limb function using Disability of Arm, Shoulder, and Hand (DASH) score of patients with primary musculoskeletal sarcoma around the forearm treated with AO therapy, compared to that of patients treated with conventional wide resection.
Subjects were 18 patients with primary musculoskeletal sarcoma around the forearm and treated with AO therapy (AO: n = 8) after marginal or intralesional resection, or conventional wide resection followed by limb reconstruction surgery (WR: n = 10).
Mean age of the 18 patients was 45 years, and mean durations of follow-up for Groups AO and WR were 67 and 74.1 months. Local recurrence rates for AO and WR were 12.5% and 20% (P = 0.63), DASH disability scores were 3.9 and 21 (P = 0.04), and 5-year survival rates were 100% and 90% (P = 0.40), respectively.
AO therapy offers maintenance of excellent upper limb function and inhibition of local tumor recurrence, representing a useful modality for limb salvage surgery in patients with sarcoma around the forearm.
我们最近开发并建立了一种新的联合光动力疗法和放动力疗法的外科治疗方法,在肿瘤边缘或局部切除后使用吖啶橙(AO)治疗,为肉瘤患者提供了优异的肢体功能。本研究评估了使用 AO 治疗的前臂原发性肌肉骨骼肉瘤患者的局部复发率和上肢功能,采用手臂、肩部和手部残疾(DASH)评分与接受传统广泛切除术治疗的患者进行比较。
研究对象为 18 例前臂原发性肌肉骨骼肉瘤患者,在肿瘤边缘或局部切除后接受 AO 治疗(AO 组:n = 8),或接受传统广泛切除后行肢体重建手术(WR 组:n = 10)。
18 例患者的平均年龄为 45 岁,AO 组和 WR 组的平均随访时间分别为 67 和 74.1 个月。AO 组和 WR 组的局部复发率分别为 12.5%和 20%(P = 0.63),DASH 残疾评分分别为 3.9 和 21(P = 0.04),5 年生存率分别为 100%和 90%(P = 0.40)。
AO 治疗可维持优异的上肢功能并抑制局部肿瘤复发,为前臂肉瘤患者的保肢手术提供了一种有用的方法。